PepGen Inc (PEPG) ニュース

Form 8-K - Current report

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

-Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled- PepGen Inc. (Nasdaq: PEPG), a...

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

– FREEDOM-DM1 data from 5 and 10 mg/kg cohorts in patients with DM1 expected in the first quarter of 2025 – – Study designs of CONNECT program...

PepGen to Participate in Upcoming Investor Conferences

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

Form 8-K - Current report

PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

Form 8-K - Current report

PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

Form 8-K - Current report

PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]